Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
A pending certificate state exposes no assay values
Use of NOVOLOG for this indication is supported by evidence from an adequate and well-controlled study in 283 pediatric patients with type 1 diabetes mellitus aged 6 to 18 years and from studies in adults with diabetes mellitus [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14)]
Significant improvements in beta-cell activity are indicated by HOMA2-B percent change from baseline increases ranging from 93 to 163% for tirzepatide (5, 10, and 15 mg doses), outperforming dulaglutide and placebo effects
doi:10.1007/s11154-021-09699-1
US$ 22.78
US$ 21.95
US$ 26.89
US$ 24.55
US$ 24.16
US$ 29.43
US$ 25.60
US$ 26.04
US$ 23.72
US$ 21.38
US$ 26.83
US$ 29.33
US$ 27.75
